卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體
Monoclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT)
phosphatidylcholine-sterol O-acyltransferase; Phospholipid-cholesterol acyltransferase
- 編號(hào)MAJ516Hu22
- 物種Homo sapiens (Human，人)相同的名稱(chēng)，不同的物種。
- 來(lái)源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))C15
- Ig亞型 IgG2b Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原RPJ516Hu01-卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/mL
- 且適物種Sus scrofa; Porcine (Pig，豬)
- 應(yīng)用WB; IHC
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格20μl100μl200μl1ml10ml
- 價(jià)格¥ 684¥ 1596¥ 2280¥ 5700¥ 22800
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
DAB staining on IHC-P; Sample: Porcine Kidney Tissue; Primary Ab: 10μg/ml Mouse Anti-Human LCAT Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
DAB staining on IHC-P;
Sample: Porcine Cerebrum Tissue;
Primary Ab: 10μg/ml Mouse Anti-Human LCAT Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
DAB staining on IHC-P;
Sample: Porcine Liver Tissue;
Primary Ab: 10μg/ml Mouse Anti-Human LCAT Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
Western Blot; Sample: Lane1: HepG2 cell lysate; Lane2: U2OS cell lysate; Lane3: Hela cell lysate Primary Ab: 1μg/ml Mouse Anti-Human LCAT Antibody Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)LCAT的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別LCAT。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPJ516Hu01 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPJ516Hu02 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APJ516Hu01 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAJ516Hu01 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)多克隆抗體 | WB; IHC; ICC; IP. |
| PAJ516Hu02 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)多克隆抗體 | WB; IHC; ICC; IP. |
| LAJ516Hu71 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAJ516Hu21 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC |
| MAJ516Hu25 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAJ516Hu27 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAJ516Hu29 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAJ516Hu24 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAJ516Hu26 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAJ516Hu28 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC; ICC; IP. |
| MAJ516Hu22 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC |
| MAJ516Hu23 | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)單克隆抗體 | WB; IHC; ICC; IP. |
| SEJ516Hu | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCJ516Hu | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMJ516Hu | 卵磷脂膽固醇脂酰轉(zhuǎn)移酶(LCAT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Int J Rheum Dis | Plasma phospholipase, γ‐CEHC and antioxidant capacity in fibromyalgia[PubMed: 26585319] |
| Inflammation. | Alteration?of?Lysophosphatidylcholine-Related?Metabolic?Parameters?in the?Plasma?of?Mice?withExperimental?Sepsis.[pubmed:28028754] |
| British journal of cancer | A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.[pubmed:28664912] |
| Journal?of?Agricultural?and?Food?Chemistry | Lipid-lowering effects of medium-chain triglyceride-enriched coconut oil in combination with licorice extracts in experimental hyperlipidemic mice[Pubmed: 30244576] |
| Experimental and Therapeutic Medicine | Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D?LC?MS/MS[Doi: 10.3892/etm.2018.6818] |
| British Journal of Cancer | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.[Pubmed: 31388184] |
| BIOMEDICINE & PHARMACOTHERAPY | The synergistic mechanism of total saponins and flavonoids in Notoginseng? Safflower pair against myocardial ischemia uncovered by an integrated?…[Pubmed: 32739736] |
| Biomedicine & Pharmacotherapy | Pharmacokinetics/pharmacometabolomics-pharmacodynamics reveals the synergistic mechanism of a multicomponent herbal formula, Baoyuan decoction??-[] |
| Cell Metab | Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression[Pubmed:35235775] |